Detecting 6 Biomarkers on a Single Tissue Section: How Powerful is mIHC?

mIHC is a multiplex immunodetection technology based on fluorescent labeling and tyramide signal amplification (TSA). Through this technology, researchers can detect multiple protein biomarkers on the same tissue section while preserving spatial information, enabling "spatial omics" analysis.

Traditional IHC is limited by the number of staining channels and antibody species cross-reactivity issues, while mIHC breaks through these limitations through the following core principles:

1. TSA Signal Amplification

   • Enzymatic reaction generates fluorescent deposits that label the target protein location.

   • Signal intensity is 10-100 times higher than traditional fluorescence.

   • Even low-expression proteins can be clearly visible.

2. Cyclic Staining and Antibody Stripping

   • Each round detects one antigen, followed by removal of primary/secondary antibodies without affecting tissue structure.

   • The next round of staining can use different fluorescence channels, and after multiple rounds of accumulation, multi-biomarker co-localization is achieved.

3. Multi-channel Fluorescence Imaging

   • Through multispectral imaging technology, overlapping fluorescence signals can be deconvolved to resolve the spatial distribution of different biomarkers.

In short, mIHC allows you to "see the full picture with one tissue section" while maintaining tissue spatial information, which is unmatched by traditional IHC.

Note: Strict antibody stripping is required after each round of cyclic staining, otherwise cross-signaling may occur.

Assuming we detect 6 immune-related biomarkers on a tumor tissue section: CD8, TIM-3, PD-1, CD68, LAG3, CK, we can obtain the following advantages:

Through multi-channel overlay imaging, we can see:

• T cell infiltration distribution (CD8)
• Immune checkpoint expression (PD-1/ TIM-3/ LAG-3)
• Macrophage to tumor cell ratio (CD68/CK)

Adding immune cell proliferation status (Ki-67), a single tissue section can simultaneously obtain a panoramic view of the immune microenvironment, saving valuable samples while improving data comparability.

1. Tumor Immune Microenvironment Analysis

   In tumor immunotherapy research, mIHC can simultaneously detect T cell subsets, immune checkpoints, and tumor cell markers, helping to screen for responding patients.

2. Rare Cell Population Identification

   In inflammation or regeneration research, rare regulatory cells or stem cell subsets are difficult to detect through single-marker IHC. mIHC significantly improves detection accuracy through multi-biomarker combination identification.

3. Drug Development and Efficacy Evaluation

   Multiplex detection of drug targets can be completed on a single tissue section, providing intuitive and quantitative spatial data for pharmacodynamic studies.

Although mIHC has obvious advantages, there are still challenges:

• Antibody cross-interference → Use strict stripping steps and species/homology-optimized antibody combinations.
• Fluorescence photobleaching → Choose stable fluorescent dyes or rapid imaging, and avoid repeated light exposure.
• Complex imaging and analysis → Utilize multispectral microscopes and AI image analysis software to improve resolution and data reproducibility.
• Experimental cost → Although reagent costs are higher than traditional IHC, it saves tissue sections and experimental repetition costs, with significantly improved overall cost-effectiveness.

Detecting 8 biomarkers on a single tissue section is not science fiction, but a real capability of mIHC technology.

For scenarios such as tumor immune microenvironment, drug development, and rare cell population research, mIHC has become an indispensable "research tool."

If you are still troubled by limited samples, multiple experimental repetitions, and insufficient information, mIHC may be the key to breaking through your challenges.